Ratios

		vs industry	vs history
P/E(ttm)	8.40	IPXL's P/E(ttm) is ranked higher than 79% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 29.76 vs. IPXL: 8.40 )	IPXL' s 10-Year P/E(ttm) Range Min: 4.03   Max: 270.57 Current: 8.4 4.03 270.57
P/B	1.83	IPXL's P/B is ranked higher than 70% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.00 vs. IPXL: 1.83 )	IPXL' s 10-Year P/B Range Min: 1.32   Max: 18.21 Current: 1.83 1.32 18.21
P/S	2.09	IPXL's P/S is ranked higher than 51% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.32 vs. IPXL: 2.09 )	IPXL' s 10-Year P/S Range Min: 1.17   Max: 82.81 Current: 2.09 1.17 82.81
EV-to-EBIT	13.48	IPXL's EV-to-EBIT is ranked higher than 82% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 21.70 vs. IPXL: 13.48 )	IPXL' s 10-Year EV-to-EBIT Range Min: 1.8   Max: 628.6 Current: 13.48 1.8 628.6
PEG	0.13	IPXL's PEG is ranked lower than 62% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.23 vs. IPXL: 0.13 )	IPXL' s 10-Year PEG Range Min: 0   Max: 0.4 Current: 0.13 0 0.4
Shiller P/E	13.36	IPXL's Shiller P/E is ranked higher than 96% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 30.12 vs. IPXL: 13.36 )	IPXL' s 10-Year Shiller P/E Range Min: 11.19   Max: 125.88 Current: 13.36 11.19 125.88

Valuation & Return

		vs industry	vs history
Price/Net Cash	10	IPXL's Price/Net Cash is ranked higher than 94% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 9.70 vs. IPXL: 10 )	IPXL' s 10-Year Price/Net Cash Range Min: 8.1   Max: 11.1 Current: 10 8.1 11.1
Price/Net Current Asset Value	10.9	IPXL's Price/Net Current Asset Value is ranked higher than 82% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 10.20 vs. IPXL: 10.9 )	IPXL' s 10-Year Price/Net Current Asset Value Range Min: 5.3   Max: 134.4 Current: 10.9 5.3 134.4
Price/Tangible Book	2.1	IPXL's Price/Tangible Book is ranked higher than 66% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 3.40 vs. IPXL: 2.1 )	IPXL' s 10-Year Price/Tangible Book Range Min: 2.3   Max: 23.6 Current: 2.1 2.3 23.6
Price/DCF (Projected)	1.8	IPXL's Price/DCF (Projected) is ranked higher than 89% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 1.60 vs. IPXL: 1.8 )	IPXL' s 10-Year Price/DCF (Projected) Range Min: 1.9   Max: 2.1 Current: 1.8 1.9 2.1
Price/Median PS Value	0.4	IPXL's Price/Median PS Value is ranked higher than 60% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 0.70 vs. IPXL: 0.4 )	IPXL' s 10-Year Price/Median PS Value Range Min: 0.3   Max: 15.3 Current: 0.4 0.3 15.3
Price/Graham Number	1.4	IPXL's Price/Graham Number is ranked higher than 73% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 2.30 vs. IPXL: 1.4 )	IPXL' s 10-Year Price/Graham Number Range Min: 0.8   Max: 1.8 Current: 1.4 0.8 1.8
Earnings Yield (Greenblatt)	7.40	IPXL's Earnings Yield (Greenblatt) is ranked higher than 85% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 5.90 vs. IPXL: 7.40 )	IPXL' s 10-Year Earnings Yield (Greenblatt) Range Min: 0.2   Max: 55.9 Current: 7.4 0.2 55.9
Forward Rate of Return (Yacktman)	1.81	IPXL's Forward Rate of Return (Yacktman) is ranked higher than 99% of the 375 Companies in the Global Drug Manufacturers - Specialty & Generic industry. ( Industry Median: 9.82 vs. IPXL: 1.81 )	IPXL' s 10-Year Forward Rate of Return (Yacktman) Range Min: -5.7   Max: 2.6 Current: 1.81 -5.7 2.6

Business Description

Impax Laboratories, Inc. was incorporated in the State of Delaware in 1995. It is a technology-based, specialty pharmaceutical company focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. Bioequivalent pharmaceuticals, commonly referred to as 'generics,' are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under its established nonproprietary drug names rather than by a brand name. Bioequivalent pharmaceuticals contain the same active ingredient and are of the same route of administration, dosage form, strength and indication(s) as brand-name pharmaceuticals already approved for use in the United States by the Food and Drug Administration ('FDA'). In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas and having technically challenging drug-delivery mechanisms or limited competition. The Company has two reportable segments, referred to as the 'Global Pharmaceuticals Division', ('Global Division') and the 'Impax Pharmaceuticals Division', ('Impax Division'). The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Company's Impax Division is engaged in the development of proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The active chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. generi
Company Website
SEC Reports

Industry:	Drug Manufacturers - Specialty & Generic
Compare:	TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:	ILR.Germany

» More Articles for IPXL

Headlines

Articles On GuruFocus.com

President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011

Joel Greenblatt’s New Magic Formula Stocks: IDCC, SNDK, MHP, OSK, LO, MRX, MSFT, IPXL, CECO, FRX, Feb 18 2011

Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010

Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010

Personalized Checklist